Want to see ZVRA full AI Analyst Report?
ZVRA Stock Chart & Stats
$10.67
$0.38(4.61%)
At close: 4:00 PM EST
$10.67
$0.38(4.61%)
Day’s Range― - ―
52-Week Range$7.16 - $14.27
Previous CloseN/A
Volume189.47K
Average Volume (3M)2.15M
Market Cap
$826.43M
Enterprise Value$650.99M
Total Cash (Recent Filing)$95.59M
Total Debt (Recent Filing)$1.15M
Price to Earnings (P/E)6.4
Beta0.82
Next Earnings
Aug 18, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding59,115,086
10 Day Avg. Volume2,405,586
30 Day Avg. Volume2,146,491
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.20
Price to Sales (P/S)4.65
P/FCF Ratio-203.69
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.32
Enterprise Value/Gross Profit6.23
Enterprise Value/Ebitda4.63
Forecast
1Y Price Target
$28.25Price Target Upside164.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.1
Revenue Forecast (FY)$147.85M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet & Strong CashEliminating debt and holding ~$237M in cash materially reduces financing risk and interest burden, providing durable flexibility to fund commercialization, patient access programs, and trials without immediate dilution. This balance sheet strength supports 2–6 month operational runway and strategic optionality.
Commercial Traction & Clinical Guideline InclusionGuideline inclusion and multi-year patient data create a sustainable competitive advantage by validating clinical benefit, easing payer conversations, and supporting durable uptake. Combined with early prescription enrollments, this underpins recurring net sales and long-term market access for a rare-disease franchise.
Long Patent Exclusivity PathPursuing Orange Book listing and a patent through 2041 materially extends exclusivity and raises barriers to generic entry. This structural protection supports sustained pricing power and revenue predictability for MIPLYFFA over multiple years, enhancing long-term return on commercial and R&D investments.
Bears Say
Operating Profit Remains NegativeReported net income is driven partly by non-operating items, masking that core operating profitability remains negative. Persistent negative EBIT implies commercial margins must improve or expenses must be controlled to sustain profit without reliance on one-time gains, a fundamental sustainability risk.
Weak, Volatile Cash GenerationOperating cash flow is small relative to reported net income and has been highly volatile historically. Weak cash conversion reduces internal funding capacity for growth and trials, increases reliance on non-recurring transactions or financing, and raises uncertainty around sustaining operations over the medium term.
Event-driven Trial Timeline RiskAn event-driven Phase III with slow accrual materially lengthens regulatory timelines and postpones potential approval and commercial upside. Prolonged trial duration increases cumulative R&D spend, delays peak sales realization, and elevates execution risk for a key pipeline asset.
Zevra Therapeutics News
ZVRA FAQ
What was Zevra Therapeutics, Inc.’s price range in the past 12 months?
Zevra Therapeutics, Inc. lowest stock price was $7.16 and its highest was $14.27 in the past 12 months.
What is Zevra Therapeutics, Inc.’s market cap?
Zevra Therapeutics, Inc.’s market cap is $826.43M.
When is Zevra Therapeutics, Inc.’s upcoming earnings report date?
Zevra Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.
How were Zevra Therapeutics, Inc.’s earnings last quarter?
Zevra Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.081 by $0.519.
Is Zevra Therapeutics, Inc. overvalued?
According to Wall Street analysts Zevra Therapeutics, Inc.’s price is currently Undervalued.
Does Zevra Therapeutics, Inc. pay dividends?
Zevra Therapeutics, Inc. does not currently pay dividends.
What is Zevra Therapeutics, Inc.’s EPS estimate?
Zevra Therapeutics, Inc.’s EPS estimate is 0.11.
How many shares outstanding does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. has 59,115,086 shares outstanding.
What happened to Zevra Therapeutics, Inc.’s price movement after its last earnings report?
Zevra Therapeutics, Inc. reported an EPS of $0.6 in its last earnings report, beating expectations of $0.081. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Zevra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ZVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zevra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.25 (164.76% Upside)
$28.25 (164.76% Upside)
Blogger Sentiment
Bearish
ZVRA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 113.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 20.4%
Last 30 Days ▲ 20.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.56%
12-Months-Change
Fundamentals
Return on Equity
81.34%
Trailing 12-Months
Asset Growth
61.30%
Trailing 12-Months
Company Description
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
ZVRA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong progress on multiple fronts: very robust revenue growth (+78% YoY), positive reported net income driven by a strategic asset sale, a clean balance sheet with no debt and meaningful commercial validation for MIPLYFFA (170 enrollments, guideline inclusion, broad clinical dataset). At the same time, management flagged a number of operational and execution items to monitor — elevated operating expenses, a sizeable tax provision, reliance on a one-time sale for headline profitability, variability in EAP and international orders, modest quarter-over-quarter prescription momentum (9 new enrollment forms in Q1), and slow event accrual in the Celiprolol trial. Overall, the positives around commercial traction, cash position and strategic portfolio actions outweigh the transitory and execution-related headwinds, but the underlying operating performance and trial timelines warrant continued attention.View all ZVRA earnings summariesZVRA Stock 12 Month Forecast
Average Price Target
$28.25
▲(164.76% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Prothena
―
Ocugen
―
Corvus Pharmaceuticals
―
Solid Biosciences
―
Ownership Overview
1.49% Insiders
13.31% Mutual Funds
26.78% Other Institutional Investors
44.98% Public Companies and Individual Investors